Introduction to Nanomedicine, 7.5 credits
Academic year 2022/2023
Autumn 2022, 100%, Campus
Start date: 30 November 2022
End date: 15 January 2023
Application deadline: 19 April 2022
Application code: UU-39005 Application
Language of instruction: English
Selection: Higher education credits in science and engineering (maximum 240 credits)
Registration: 23 November 2022 – 30 November 2022
Entry requirements: For students from the:
Master of Sciences Programmes in Pharmacy and Chemical Engineering the student should have at least 150 credits in the programme, and passed the programme course(s) in physical chemistry and pharmaceutics.
Master Programme in Drug Discovery and Development the student should have passed the course in Molecular Biopharmaceutics.
For acceptance to freestanding course at least 150 credits are required including at least 15 credits in physical chemistry, pharmaceutics and pharmacokinetics.
Knowledge in English equivalent to what is required for basic eligibility to Swedish higher education.
If you are not a citizen of a European Union (EU) or European Economic Area (EEA) country, or Switzerland, you are required to pay application or tuition fees. Formal exchange students will be exempted from tuition fees, as well as the application fee. Read more about fees.
Application fee: SEK 900
Tuition fee, first semester: SEK 18,125
Tuition fee, total: SEK 18,125
About the course
The course covers the principles in nanomedicine, especially with regard to the connection between physicochemical properties of nanomaterials, possible administration routes and their interactions with cells and tissues in the body. Further, it deals with the behaviour of nanoparticles in biological fluids (e.g. plasma, intestinal fluid) and colloidal stability.
We study the basic principles for active (with ligands) and passive (e.g. for cancer therapy) targeting and uptake of nanoparticles in cells and tissues in the body. Furthermore, the course will cover nanoparticle and nanocarrier properties including the most important synthesis routes and characterisation methods. Special focus is also on diagnostic materials that can be used in imaging techniques or in theranostic formulations that combine disease diagnosis and therapy.
Finally, we will consider toxic, pharmacokinetic and regulatory aspects of nanomaterials in biomedical applications. For toxicity, this includes a comparison of different external barriers that are exposed to nanomaterials, e.g. in the intestine, lungs, nose and skin.
Biomedicinskt Centrum BMC, Husargatan 3 752 37 Uppsala
Box 580, 751 23 UPPSALA